Table 1.
Characteristics of included studies.
| Study design | Study site | Study subjects | Vaccine status | Regimen of fluvoxamine | No of study patients |
||
|---|---|---|---|---|---|---|---|
| Study group | Control group | ||||||
| Lenze et al., 2020 | double-blind, placebo-controlled, randomized clinical trial | St Louis metropolitan area, US | Non-hospitalized adults with COVID-19 | Unvaccinated | 50- to 100-mg loading dose, then 100 mg thrice daily for 15 days | 80 | 72 |
| Reis et al., 2021 | placebo-controlled, randomized, adaptive platform trial | 11 clinical sites in Brazil | Non-hospitalized adults with COVID-19 and a known risk factor for progression to severe disease | Unvaccinated | 100 mg twice daily for 10 days | 741 | 756 |
| Seftel et al., 2021 | Prospective open-label cohort study | California, US | Non-hospitalized patients with COVID-19 | NA | 50- to 100-mg loading dose, then 50 mg twice daily for 14 days | 65 | 48 |
| Seo et al., 2022 | placebo-controlled, randomized trial | Seoul, Korea | Non-hospitalized adults with COVID-19 | NA | 100 mg twice daily for 10 days | 26 | 26 |
NA, not applicable.